Flt-1-dependent survival characterizes the epithelial-mesenchymal transition of colonic organoids

被引:104
作者
Bates, RC
Goldsmith, JD
Bachelder, RE
Brown, C
Shibuya, M
Oettgen, P
Mercurio, AM
机构
[1] Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA
[2] Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA
[3] Harvard Univ, Sch Med, Boston, MA 02215 USA
[4] Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo 1088639, Japan
关键词
D O I
10.1016/j.cub.2003.09.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Aberrant cell survival and resistance to apoptosis are hallmarks of tumor invasion and progression to metastatic disease [1], but the mechanisms involved are poorly understood. The epithelial-mesenchymal transition (EMT), a process that facilitates progression to invasive cancer, provides a superb model for studying such survival mechanisms. Here, we used a unique spheroid culture system that recapitulates the structure of the colonic epithelium and undergoes an EMT in response to cytokine stimulation to study this problem [2]. Our data reveal that the EMT results in the increased expression of both VEGF and Flt-1, a tyrosine kinase VEGF receptor, and that the survival of these cells depends on a VEGF/Flt-1 autocrine pathway. Perturbation of Flt-1 function by either a blocking antibody or adenoviral expression of soluble Flt-1, which acts in a dominant-negative fashion, caused massive apoptosis only in cells that underwent EMT. This pathway was critical for the survival of other invasive colon carcinoma cell lines, and we observed a correlative upregulation of Flt-1 expression linked to in vivo human cancer progression. A role for Flt-1 in cell survival is unprecedented and has significant implications for Flt-1 function in tumor progression, as well as in other biological processes, including angiogenesis and development.
引用
收藏
页码:1721 / 1727
页数:7
相关论文
共 37 条
  • [21] Mahasreshti PJ, 2001, CLIN CANCER RES, V7, P2057
  • [22] Therapies directed at vascular endothelial growth factor
    Manley, PW
    Martiny-Baron, G
    Schlaeppi, JM
    Wood, JM
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (12) : 1715 - 1736
  • [23] TGF-beta 1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells
    Oft, M
    Peli, J
    Rudaz, C
    Schwarz, H
    Beug, H
    Reichmann, E
    [J]. GENES & DEVELOPMENT, 1996, 10 (19) : 2462 - 2477
  • [24] TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis
    Oft, M
    Heider, KH
    Beug, H
    [J]. CURRENT BIOLOGY, 1998, 8 (23) : 1243 - 1252
  • [25] PARK JE, 1994, J BIOL CHEM, V269, P25646
  • [26] Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition
    Savagner, P
    [J]. BIOESSAYS, 2001, 23 (10) : 912 - 923
  • [27] Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans
    Sawano, A
    Iwai, S
    Sakurai, Y
    Ito, M
    Shitara, K
    Nakahata, T
    Shibuya, M
    [J]. BLOOD, 2001, 97 (03) : 785 - 791
  • [28] Vascular endothelial growth factor-mediated autocrine stimulation of prostate tumor cells coincides with progression to a malignant phenotype
    Soker, S
    Kaefer, M
    Johnson, M
    Klagsbrun, M
    Atala, A
    Freeman, MR
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 159 (02) : 651 - 659
  • [29] Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma
    Strizzi, L
    Catalano, A
    Vianale, G
    Orecchia, S
    Casalini, A
    Tassi, G
    Puntoni, R
    Mutti, L
    Procopio, A
    [J]. JOURNAL OF PATHOLOGY, 2001, 193 (04) : 468 - 475
  • [30] Takayama K, 2000, CANCER RES, V60, P2169